Asim Amin1, Elizabeth R Plimack2, Marc S Ernstoff3, Lionel D Lewis4, Todd M Bauer5, David F McDermott6, Michael Carducci7, Christian Kollmannsberger8, Brian I Rini9, Daniel Y C Heng10, Jennifer Knox11, Martin H Voss12, Jennifer Spratlin13, Elmer Berghorn14, Lingfeng Yang14, Hans J Hammers15. 1. Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, Charlotte, NC, 28204, USA. Asim.Amin@carolinashealthcare.org. 2. Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. 3. Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14203, USA. 4. Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA. 5. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, 37203, USA. 6. Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, 02215, USA. 7. Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21287, USA. 8. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada. 9. Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, 44195, USA. 10. Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, T2N 4N2, Canada. 11. Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, M5G 1Z5, Canada. 12. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 13. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada. 14. Oncology - Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, 08541, USA. 15. Department of Internal Medicine, UT Southwestern - Kidney Cancer Program, Dallas, TX, 75390, USA.
Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:109https://doi.org/10.1186/s40425-018-0420-0Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable.” should be replaced with “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable.” (3.0% instead of 0.3%).The publisher apologizes for any inconvenience caused by this error.
Authors: Asim Amin; Elizabeth R Plimack; Marc S Ernstoff; Lionel D Lewis; Todd M Bauer; David F McDermott; Michael Carducci; Christian Kollmannsberger; Brian I Rini; Daniel Y C Heng; Jennifer Knox; Martin H Voss; Jennifer Spratlin; Elmer Berghorn; Lingfeng Yang; Hans J Hammers Journal: J Immunother Cancer Date: 2018-10-22 Impact factor: 13.751
Authors: Arkadiusz Z Dudek; Li C Liu; Shilpa Gupta; Theodore F Logan; Eric A Singer; Monika Joshi; Yousef N Zakharia; Joshua M Lang; James K Schwarz; Anas Al-Janadi; Ajjai S Alva Journal: J Clin Oncol Date: 2020-02-25 Impact factor: 44.544